Profound Medical (TSE:PRN) Hits New 1-Year Low – Should You Sell?

Profound Medical Corp. (TSE:PRN)’s stock price reached a new 52-week low on Monday . The stock traded as low as C$8.23 and last traded at C$8.23, with a volume of 2578 shares. The stock had previously closed at C$8.55.

Wall Street Analyst Weigh In

Separately, Raymond James upgraded shares of Profound Medical to a “strong-buy” rating in a research report on Saturday, November 9th.

Profound Medical Price Performance

The business has a 50 day simple moving average of C$10.17 and a two-hundred day simple moving average of C$11.07. The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61. The firm has a market capitalization of C$218.36 million, a P/E ratio of -5.37 and a beta of 0.81.

Insider Buying and Selling

In other news, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was acquired at an average price of C$10.65 per share, for a total transaction of C$141,996.45. Also, Director Arun Menawat Dr. acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of C$10.65 per share, for a total transaction of C$213,000.00. 8.62% of the stock is owned by corporate insiders.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.